Loading [MathJax]/jax/output/SVG/jax.js
中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 9
Sep.  2017

Effect of arsenic trioxide chemotherapy on survival time in liver cancer patients undergoing liver transplantation

DOI: 10.3969/j.issn.1001-5256.2017.09.023
Research funding:

 

  • Received Date: 2017-03-06
  • Published Date: 2017-09-20
  • Objective To investigate whether arsenic trioxide preventive chemotherapy can prolong the survival time of patients with primary liver cancer undergoing liver transplantation. Methods A retrospective analysis was performed for the clinical data of the patients who underwent liver transplantation in Department of Liver Transplantation in Changzheng Hospital from January to December, 2015, and among these patients, 35 ( observation group) received the chemotherapeutic regimen of epirubicin D1 + 5-fluorouracil ( D1-5) and 35 ( control group) received the chemotherapeutic regimen of arsenic trioxide ( D1-14) . Hematological examinations were performed at the beginning and ending of each cycle of treatment, including routine blood test, hepatic and renal function, and tumor markers, and drug side-effects were observed. Chest CT, liver CT, or MRI was performed at the beginning of every two cycles to record tumor recurrence, survival, and death time. The chi-square test was used for comparison of categorical data between groups, the Kaplan-Meier method was used to plot survival curves, and the log-rank test was used to compare survival curves between groups. Results In the observation group, 3 patients experienced a transient increase in alanine aminotransferase after the last chemotherapy; 30 patients experienced the symptoms of water-sodium retention including mild edema in the face and lower limbs in the late stage of treatment, which were improved after diuretic treatment or at the end of treatment. In the control group, 24 patients experienced varying degrees of gastrointestinal reactions such as poor appetite, nausea, and vomiting, which were improved at the end of chemotherapy. The control group had a 1-year survival rate of 85. 7% ( 30/35) , a 2-year survival rate of 47. 4% ( 18/35) , and a 3-year survival rate of 22. 9% ( 8/35) , and the observation group had a 1-year survival rate of 91. 4% ( 32/35) , a 2-year survival rate of 83. 9% ( 26/31) , and a 3-year survival rate of 57. 1% ( 12/21) . There was no significant difference in 1-year survival rate between the two groups ( χ2= 2. 258, P < 0. 05) , and the observation group had significantly higher 2-and 3-year survival rates than the control group ( χ2= 7. 786 and 6. 720, both P < 0. 05) . Survival curves also showed that the observation group had significantly higher 2-and 3-year survival rates than the control group ( χ2= 6. 573, P < 0. 05) . Conclusion Arsenic trioxide has been used for a long time, and with modern and scientific administration, it can improve the survival time of patients with liver cancer undergoing liver transplantation.

     

  • 检验项目参考区间是临床疾病诊断与健康监测的主要依据,参考区间的准确性、适用性直接影响着临床判断。2012年,我国卫生行业标准发布了血清AST、ALT、GGT、ALP等项目的参考区间,同时指出该参考区间可能受民族、地区影响而致其不适用,各实验室可自行建立参考区间[1]。目前建立参考区间的方法有直接法[2]和间接法[3],直接法需通过建立严格的排除标准而筛选符合要求的参考个体,且此法过程漫长繁琐、难以实施;而间接法只需通过数学统计,凭借快速简便、能得到与直接法相似结果的优势脱颖而出。本研究利用临床实验室信息系统(laboratory information system,LIS)已有数据,用数学统计模型建立AST、ALT、GGT、ALP间接法参考区间,并与国家行业标准比较,以期为临床疾病诊断与健康监测提供依据和参考。

    收集本院2019年10月—2020年10月LIS中体检中心健康人群数据,排除信息不全及溶血、脂血、黄疸等不合格样本后,通过比对样本号、姓名、年龄、就诊日期等信息确认为同一来源选择首次测量结果。共入组20~79岁健康人群数据29 443例,其中男性13 423例、女性16 020例。

    使用日立公司的7600-210全自动生化分析仪、上海科华公司的试剂与标准品、美国伯乐公司的室内质控品。仪器每年由厂家进行一次校准,每日8点前至少对高、中、低值质控品进行测定(批号:45803,45802,45801)。

    AST的检测方法为紫外-苹果酸脱氢酶法,ALT的检测方法为紫外-乳酸脱氢酶法,GGT的检测方法为L-γ-谷氨酰-3-羧基-4-硝基苯氨法,ALP的检测方法为AMP缓冲液法。研究对象空腹8 h后于次日上午7∶ 30—9∶ 30安坐,自肘前静脉真空采血4 ml,常温送至检验科进行上述4种生化指标检测。

    本研究方案经由吉林大学第一医院伦理委员会批准,批号:2019-249。

    利用SPSS 23.0、Minitab 17、LMS chartmaker Light 2.54、Excel 2016软件分析数据。柯尔莫哥洛夫-斯米诺夫检验判断数据正态性,若其呈偏态分布则使用BOC-COX法转换,此法中的待定变换参数λ由极大似然法求得,其值由所有数据决定。BOX-COX法可针对不同的λ做出不同变换。转换后的数据经P-P图检验为近似正态分布后,使用Turkey法剔除离群值。剔除时把四项指标视为一个整体,若其中任意一个指标符合剔除标准则剔除此人全部信息。Spearman相关分析判断AST、ALT、GGT、ALP与年龄的相关性。LMS法建立连续百分位数曲线。Mann-Whitney U检验比较性别差异,5岁为一年龄组,Z检验比较年龄差异。用数据均值、标准方差及样本量计算ZZ*值,如ZZ*则差异有统计学意义,需分组建立参考区间[2]。非参数法计算数据分布的2.5%和97.5%百分位值作为参考区间的上、下限,并用Bootstrap计算其90%置信区间。P < 0.05为差异有统计学意义。

    选取本院2020年11月体检中心20~79岁健康人群作为验证个体,对新建立的参考区间进行适用性验证[4],并参照我国行业标准:参考个体多于20例且落在参考区间内的数据≥90%,则通过验证。计算各指标参考区间上、下限值与我国行业标准及其他研究的相对偏差,并与相应参考变化值(reference change value,RCV)比较,其中RCV的计算公式为 RCV=2×Z×CV2a+CV2i(CVa为分析变异系数、CVi为个体内生物学变异系数,通过Westgard网站获得;Z为差异的可能性概率,95%的可能性概率取值1.96),若相对偏差>RCV则认为二者间差异有统计学意义。

    调取的AST、ALT、GGT、ALP数据均不服从正态分布,使用BOX-COX法将其转换为近似正态分布,其中四组数据的待定变换参数λ分别为-0.80、-0.78、0.25、-0.10。使用Turkey法剔除数据2225例,其中男性1213例,女性1012例。正态转换及离群值剔除前后具体数据详见表 1

    表  1  BOX-COX变换及剔除前后数据分布
    指标 数据类型 样本量(例) 均值 标准差 全距 中位数 P25 P75
    AST (U/L) 原始数据 29 443 21.39 9.11 219.70 19.30 16.40 23.60
    转换后 29 443 0.09 0.02 0.33 0.09 0.08 0.11
    剔除后 27 218 20.58 6.14 40.10 19.20 16.40 23.10
    ALT (U/L) 原始数据 29 443 22.69 17.08 385.90 17.80 12.60 26.70
    转换后 29 443 0.11 0.05 1.70 0.11 0.08 0.14
    剔除后 27 218 21.29 13.01 122.80 17.60 12.70 25.50
    GGT (U/L) 原始数据 29 443 25.51 20.39 149.20 18.70 12.50 26.70
    转换后 29 443 2.17 0.37 2.59 2.09 1.89 2.37
    剔除后 27 218 22.91 14.51 75.80 18.20 12.50 28.90
    ALP (U/L) 原始数据 29 443 60.38 17.50 313.90 58.00 48.30 69.70
    转换后 29 443 0.66 0.02 0.22 0.66 0.64 0.67
    剔除后 27 218 59.94 15.90 92.80 57.90 48.30 69.30
    注:剔除部分为离群值。
    下载: 导出CSV 
    | 显示表格

    Mann-Whitney U检验结果显示,AST在20~54岁性别间差异有统计学意义(7个年龄段Z值分别为-5.68、-15.59、-30.14、-25.86、-19.22、-15.12、-4.29,P值均 < 0.05)。ALT、GGT、ALP在各年龄组不同性别间差异均有统计学意义(ALT各年龄段Z值分别为-10.27、-24.71、-39.41、-33.86、-28.14、-26.94、-15.17、-11.52、-5.90、-4.77、-3.20、-3.83;GGT各年龄段Z值分别为-12.06、-24.95、-39.70、-34.04、-31.95、-31.61、-23.33、-19.20、-13.54、-9.46、-6.29、-3.65;ALP各年龄段Z值分别为-8.32、-16.36、-22.67、-23.55、-20.42、-14.99、-4.62、-12.77、-10.20、-8.54、-5.03、-2.59,P值均 < 0.05)。Spearman相关结果显示,男性ALT(r=-0.191, P<0.001)、GGT(r=-0.041, P<0.001)与年龄呈负相关;女性AST(r=0.365, P<0.001)、ALT(r=0.310, P<0.001)、GGT(r=0.264, P<0.001)及ALP(r=0.411, P<0.001)与年龄呈正相关。分组后各亚组样本量均大于120例。男性ALT、GGT及女性AST、ALT、GGT、ALP的年龄差异均有统计学意义(ZZ*)。AST、ALT、GGT、ALP水平连续百分位数曲线见图 1

    图  1  AST、ALT、GGT、ALP水平连续百分位数曲线

    用于验证的样本剔除离群值后共10 598例,其中男性6292例、女性4306例。男性、女性共14个亚组,各组验证样本量均>20例,4项生化指标均有>90%的测定值落在本研究参考区间内。使用非参数方法计算的AST、ALT、GGT、ALP参考区间及适用性验证见表 2。为与我国行业标准保持一致,本研究结果取整数。AST、ALT、GGT和女性20~49岁ALP参考区间与我国行业标准的相对偏差均低于RCV,男性及50~79岁女性ALP参考区间与我国行业标准的相对偏差高于RCV。本研究结果与国内外研究结果比较见表 3

    表  2  AST、ALT、GGT、ALP参考区间及适用性验证
    指标 分组 样本量(例) P2.5 90%置信区间 P97.5 90%置信区间 验证样本量(例) 验证通过率(%)
    性别 年龄(岁) 下限 上限 下限 上限
    AST (U/L) 20~79 12 210 13.50 13.40 13.60 39.30 38.60 39.90 6292 95.12
    20~49 10 035 12.20 12.10 12.30 32.40 31.61 33.20 2744 95.70
    50~79 4973 13.90 13.70 14.00 38.60 37.60 39.60 1562 96.16
    ALT (U/L) 20~54 8714 10.39 10.10 10.50 70.53 69.13 72.24 4544 93.90
    55~79 3496 9.90 9.54 10.00 49.26 47.77 51.47 1748 94.79
    20~49 10 035 7.40 7.30 7.40 42.60 41.20 43.81 2744 93.95
    50~79 4973 9.00 8.84 9.20 49.27 48.03 50.80 1562 94.88
    GGT (U/L) 20~64 11 195 10.50 10.39 10.80 69.90 69.11 70.50 5732 90.25
    65~79 1015 10.00 9.30 10.30 64.20 59.80 66.80 560 94.29
    20~49 10 035 6.20 6.10 6.30 44.90 43.50 46.59 2744 95.48
    50~79 4973 7.40 7.20 7.60 54.23 51.90 58.00 1562 94.30
    ALP (U/L) 20~79 12 210 37.90 37.60 38.40 95.97 95.02 97.20 6292 92.39
    20~49 10 035 33.00 32.70 33.30 88.72 87.42 90.40 2744 93.11
    50~79 4973 40.20 39.70 41.00 106.30 105.30 107.43 1562 91.87
    下载: 导出CSV 
    | 显示表格
    表  3  本研究与其他研究结果比较
    指标 本研究(间接法) 我国行业标准(直接法) 俄罗斯(直接法) 沙特阿拉伯(直接法) 我国上海(间接法) RCV(%)
    年龄(岁) 年龄(岁) 相对偏差(%) 年龄(岁) 相对偏差(%) 年龄(岁) 相对偏差(%) 年龄(岁) 相对偏差(%)
    AST (U/L) 20~79 14~39 20~19 15~45 13~40 (7.14, 15.38) 18~64 15~41 14~32 (7.14, 5.13) 18~65 11~28 10~24 (21.43, 28.21) 20~79 15~46 13~38 (7.14, 17.95) 38.12
    20~49 12~32 (8.33, 25.00) (16.67, 0) (16.67, 25.00) (8.33, 18.75) 38.12
    50~79 14~39 (7.14, 2.56) (0, 17.95) (28.57, 38.46) (7.14, 2.56) 38.12
    ALT (U/L) 20~54 10~71 20~19 9~60 1~45 (10.00, 15.49) 18~64 11~51 7~31 (10.00, 28.17) 18~65 7~39 5~18 (30.00, 45.07) 20~79 8~555 5~42 (20.00, 22.54) 60.12
    55~19 10~49 (10.00, 22.45) (10.00, 4.08) (30.00, 20.41) (20.00, 12.24) 60.12
    20~49 7~43 (0, 4.65) (0, 27.91) (28.57, 58.14) (28.57, 7.69) 60.12
    50~79 9~49 (22.22, 8.16) (22.22, 36.73) (44.44, 63.27) (44.44, 2.33) 60.12
    GGT (U/L) 20~64 11~70 20~19 10~60 1~45 (9.09, 13.m) 18~64 12~69 8~32 (9.09, 0) 18~65 11~65 7~21 (0, 5.80) 20~79 16~52 8~39 (45.45, 25.71) 41.53
    65~79 10~64 (0, 6.25) (20.00, 7.81) (10.00, 1.56) (60.00, 18.75) 41.53
    20~49 6~45 (16.66, 0) (33.33, 28.89) (16.67, 53.33) (33.33, 13.33) 41.53
    50~79 7~54 (0, 16.66) (14.29, 40.74) (0, 61.11) (14.29, 27.78) 41.53
    ALP (U/L) 20~79 38~96 20~19 45~125 (18.42, 30.21) 18~64 46~121 (21.05, 26.04) 18~65 39~114 (2.63, 18.75) 19.99
    20~49 33~89 20~49 35~100 (6.06, 12.36) 18~44 38~89 (15.15, 0) (18.18, 28.09) 19.99
    50~79 40~106 50~19 50~135 (25.00, 27.36) 45~64 44~128 (10.00, 20.75) (2.50, 7.55) 19.99
    下载: 导出CSV 
    | 显示表格

    血清AST、ALT、GGT、ALP作为常规肝功能检测的四项指标对肝肾疾病的诊断及治疗至关重要。近年有研究表明,AST、ALT与癌细胞代谢密切相关,并与不同类型癌症的预后有关[5];ALT与非酒精性脂肪肝性肝炎的肝脏炎症、肝纤维化及肝脂肪变性程度显著相关[6]。也有研究[7]结果显示,GGT、ALP与肾脏预后独立相关。故建立其准确可靠的参考区间具有重要意义。

    本研究中男性随年龄增加,ALT、GGT水平先上升后下降,验证了我国多中心研究[8]中男性ALT、GGT水平在40岁前随年龄升高,在40岁后保持不变或下降的结论。这种趋势的可能原因是,ALT、GGT水平与酒精有关[9],人进入中老年期,中度或重度饮酒人士数量减少。本研究中女性AST、ALT、GGT、ALP水平均随年龄增加,在45~55岁时上升明显,验证了我国多中心研究[8]中女性AST、ALT、GGT、ALP与年龄正相关、我国北京[10]ALP水平在50岁后升高的结论。女性45~55岁呈现出的特殊性可能与其生理变化有关,大多数女性在该年龄段步入更年期、绝经期,性激素波动明显。本研究中男性或女性ALT水平在60岁后均有不同程度下降,验证了美国老年人ALT水平与年龄呈负相关的研究结果[11],提示临床医生在解释患者(尤其是老年人)ALT水平时应考虑年龄因素。

    通过相对偏差与RCV比较,本研究自建的男性ALP参考区间上限、女性50~79岁ALP参考区间上、下限与我国行业标准间差异有统计学意义(相对偏差>RCV)。男性GGT参考区间下限与我国上海的研究[12]、女性AST、GGT、ALP参考区间上限与沙特阿拉伯的研究[13]、男性ALP参考区间上、下限及50~79岁女性ALP参考区间上限与俄罗斯的研究[14]差异有统计学意义(相对偏差>RCV)。造成差异的原因可能是:(1)这4项生化指标与BMI有关[14-15],或与人群、种族、遗传、地域、生活习惯、饮食结构等有关;(2)样本量不足,纳入研究的数据不足以代替整个人群;(3)不同实验室建立参考区间的检测方法、试剂、仪器等差异;(4)可能存在异常数据,虽经过离群值剔除但不能确保纳入研究的个体为完全健康没有疾病。自建的ALP参考区间与我国行业标准间的差异可通过增加样本量来改善。另外本研究建立的参考区间通过适用性验证,表明该参考区间适用于本地区人群,证实间接法建立参考区间的可行性。此前本实验室已使用直接法建立了长春地区儿童血清AST、ALT、GGT、ALP参考区间[16-17]。直接法虽是建立参考区间的标准方法,但其过程漫长繁琐,如需面对特殊群体(新生儿、孕妇、老人等)会使数据更加难以收集。若实验室直接引用试剂厂商提供的参考区间,难免存在种族、环境等差异。而间接法利用已有数据既可获得特殊群体足够多的数据量,又无需额外投入,是一种很好的选择,适合不同实验室根据本地区人群、检测系统等实际情况建立参考区间。本研究以LIS数据为基础,运用数学统计模型建立参考区间,虽可能纳入异常数据,但通过适宜数据转换、离群值剔除后计算参考区间可有效弥补这一缺陷[8]。间接法作为一种回顾性研究,其实施过程无法达到与直接法一致的严谨程度,各界对其存在一定争议,故应定期验证间接法建立的参考区间以确保其可靠性。本研究根据数据分布及样本量选择了BOX-COX法、Turkey法与非参数法,目前尚不能评价本研究所用方法的优劣。尽管如此,间接法仍然凭借着简单快速的优势在未来有很好的应用前景。

    血清酶与性别、年龄等因素关系密切,故应根据性别及年龄建立参考区间。本研究使用间接法建立了成人血清AST、ALT、GGT、ALP的性别及年龄特异性参考区间。该参考区间与我国行业标准较为一致,证实间接法建立参考区间的可信度和可靠性。本研究为血清酶类参考区间研究提供了基础数据,有益于肝病及其他相关疾病的预防及鉴别诊断。

  • [1]KEW MC.Hepatocellular carcinoma in developing countries:prevention, diagnosis and treatment[J].World J Hepatol, 2012, 4 (3) :99-104.
    [2]FORNER A, LLOVET JM, BRUIX J.Hepatocellular carcinoma[J]Lancet, 2012, 379 (9822) :1245-1255.
    [3]ZHENG SS, YU J, ZHANG W.Current development of liver transplantation in China[J].J Clin Hepatol, 2014, 30 (1) :2-4. (in Chinese) 郑树森, 俞军, 张武.肝移植在中国的发展现状[J].临床肝胆病杂志, 2014, 30 (1) :2-4.
    [4]PFIFFER TE, SEEHOFER D, NICOLAOU A, et al.Recurrent hepatocellular carcinoma in liver transplant recipients:parameters affecting time to recurrence, treatment options and survival in the sorafenib era[J].Tumori, 2011, 97 (4) :436-441.
    [5]BYAM J, RENZ J, MILLIS JM.Liver transplantation for hepatocellular carcinoma[J].Hepatobiliary Surg Nutr, 2013, 2 (1) :22-30.
    [6]WANG Z, ZHOU J.Combined modality therapy for recurrent hepatocellular carcinoma following liver transplantation[J].Chin JHepatol, 2013, 21 (5) :324-325. (in Chinese) 王征, 周俭.肝癌肝移植术后的综合治疗[J].中华肝脏病杂志, 2013, 21 (5) :324-325.
    [7]Chinese Society of Liver Cancer, Chinese Anti-Cancer Association.Diagnostic criteria for primary liver cancer[J].Chin J Hepatol, 2000, 8 (3) :135. (in Chinese) 中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J].中华肝脏病杂志, 2000, 8 (3) :135.
    [8]FAN J, ZHOU J, XU Y, et al.Indication of liver transplantation for hepatocellular carcinoma:Shanghai Fudan Criteria[J].Natl Med JChina, 2006, 18 (3) :1227-1231. (in Chinese) 樊嘉, 周俭, 徐泱, 等.肝癌肝移植适应证的选择:上海复旦标准[J].中华医学杂志, 2006, 18 (3) :1227-1231.
    [9]RAHIMI RS, TROTTER JF.Liver transplantation for hepatocellular carcinoma:outcomes and treatment options for recurrence[J].Ann Gastroenterol, 2015, 28 (3) :323-330.
    [10]LI T, SHEN C, XIE JJ, et al.Effects of sirolimus-based immunosuppressive protocol on recurrence of hepatocellular carcinoma after liver transplantation[J].J Surg Concepts Pract, 2014, 19 (4) :301-304. (in Chinese) 李涛, 申川, 谢俊杰, 等.以西罗莫司为主的免疫抑制方案在肝细胞癌肝移植术后的应用[J].外科理论与实践, 2014, 19 (4) :301-304.
    [11]KIENLE P, WCITZ J, KLAES R, et al.Detection of isolated disseminated tumor cells in bone marrow and blood samples of patients with hepatocellular carcinoma[J].Arch Surg, 2000, 135 (2) :213-218.
    [12]ZHANG X, JIA S, YANG S, et al.Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression[J].J Cell Biochem, 2012, 113 (11) :3528-3535.
    [13]ZHANG XB, XIE JG, TAN ZM, et al.Clinical study of arsenic trioxide in the treatment of primary hepatic carcinoma by interventional ways[J].Diagn Imag Interv Radiol, 2011, 20 (1) :58-60. (in Chinese) 张新保, 谢建功, 谭章梅, 等.含三氧化二砷介入方案治疗原发性肝癌的临床研究[J].影像诊断与介入放射学, 2011, 20 (1) :58-60.
    [14]ALARIFI S, ALI D, ALKAHTANI S, et al.Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells[J].Onco Targets Ther, 2013, 6:75-84.
    [15]SHAO LL, HUANG ZP, JIANG PL, et al.Influence of arsenic trioxide on apoptosis and Bcl-2/Bax expression of hepatoma cell line Hep G2[J].Clin Educ Gen Pract, 2011, 9 (5) :490-493. (in Chinese) 邵立龙, 黄志平, 蒋萍莉, 等.三氧化二砷对肝癌Hep G2细胞凋亡及Bcl-2、Bax表达的影响[J].全科医学临床与教育, 2011, 9 (5) :490-493.
    [16]LIU WH, LI D, XIE KX, et al.Research advances of the effect of arsenic trioxide on tumor angiogenesis[J].Foreign Med Sci:Sect Medgeogr, 2015, 36 (3) :174-177. (in Chinese) 刘伟华, 李丹, 谢坤霞, 等.三氧化二砷对肿瘤血管新生作用的研究进展[J].国外医学:医学地理分册, 2015, 36 (3) :174-177.
    [17]DUAN JH, CHEN J, QIAN YM, et al.Effect of arsenic trioxide on expression of PTTG1 and VEGF in human hepatoma cancer cells in vitro[J].Int J Dig Dis, 2012, 32 (2) :114-117. (in Chinese) 段建华, 陈鉴, 钱燕敏, 等.三氧化二砷对肝癌细胞表达PT-TG1和VEGF的影响及其意义[J].国际消化病杂志, 2012, 32 (2) :114-117.
    [18]WANG X, JIANG F, MU J, et al.Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated micro RNA-491[J].Toxicol Lett, 2014, 227 (2) :75-83.
    [19]LI HY, CAO LM.Inhibitory effect of arsenic trioxide on invasion in human hepatocellular carcinoma SMMC-7721 cells and its mechanism[J].Chin J Cell Mol Immunol, 2012, 28 (12) :1254-1257. (in Chinese) 李海燕, 曹励民.三氧化二砷抑制人肝癌SMMC-772细胞侵袭及其机制[J].细胞与分子免疫学杂志, 2012, 28 (12) :1254-1257.
    [20]WANG GZ, ZHANG W, FANG ZT, et al.Arsenic trioxide:marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro[J].J Cancer Res Clin Oncol, 2014, 140 (7) :1125-1136.
    [21]WANG Z, ZHOU J.Comprehensive strategy for improving the outcome of liver transplantation in patients with hepatocellular carcinoma[J].JClin Hepatol, 2015, 31 (12) :1937-1940. (in Chinese) 王征, 周俭.提高肝癌肝移植疗效的综合策略[J].临床肝胆病杂志, 2015, 31 (12) :1937-1940.
    [22]YANG Y, ZHANG YC.The thinking of the future for liver transplantation of liver cancer[J].Ogran Transplantation, 2016, 7 (1) :1-7. (in Chinese) 杨扬, 张英才.肝癌肝移植未来方向的思考[J].器官移植, 2016, 7 (1) :1-7.
    [23]ZHAO XY, YANG S, CHEN YR, et al.Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo[J].PLo S One, 2014, 9 (6) :e98925.
    [24]CHEN M.Clinical effect of arsenic trioxide combined with Aidi injection in treatment of advanced primary liver cancer[J].Hebei Med J, 2010, 32 (15) :2027-2028. (in Chinese) 陈美.三氧化二砷联合艾迪注射液治疗晚期原发性肝癌的临床观察[J].河北医药, 2010, 32 (15) :2027-2028.
    [25]LI JJ, LI CY, LIANG S, et al.Clinical study of aidi injection[J].J Changchun Univ Chin Med, 2016, 32 (4) :878-879. (in Chinese) 李娟娟, 李超英, 梁硕, 等.艾迪注射液的临床研究[J].长春中医药大学学报, 2016, 32 (4) :878-879.
    [26]PENG GZ, YE QF, WANG L.Application of arsenic trioxide in treatment of liver cancer---drug combination[J].J Hepatopancreatobiliary Surg, 2016, 28 (6) :441-447. (in Chinese) 彭贵主, 叶啟发, 王垒.三氧化二砷治疗肝癌的出路---联合用药[J].肝胆胰外科杂志, 2016, 28 (6) :441-447.
  • Relative Articles

    [1]Decai KONG, Xiaojing ZHANG, Yangguang YUN, Haoyu DUAN, Junfeng YE. Risk factors for biliary stricture and prognosis after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(11): 2253-2259. doi: 10.12449/JCH241119
    [2]Zhiying LIU, Zhihang ZHOU, Song HE. Research advances in the role of blood metabolic markers in the treatment response and prognosis prediction of primary liver cancer[J]. Journal of Clinical Hepatology, 2023, 39(10): 2470-2475. doi: 10.3969/j.issn.1001-5256.2023.10.028
    [3]Weimeng HE, Zhiming ZHANG, Jinlin HOU, Yajing HE. Effect of entecavir antiviral therapy on the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2021, 37(3): 601-605. doi: 10.3969/j.issn.1001-5256.2021.03.019
    [4]Chengzuo HAN, Qiang WEI, Xiao XU. Transplant oncology creates a new era of liver transplantation for the treatment of liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(2): 253-256. doi: 10.3969/j.issn.1001-5256.2021.02.002
    [5]Lin CHEN, Ning LIU, Jinglan JIN, Yanjun CAI, Fang XU, Junqi NIU, Wanyu LI. Research status and challenges in the prognosis of primary biliary cholangitis after liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(4): 955-958. doi: 10.3969/j.issn.1001-5256.2021.04.050
    [6]Xing DAI, Ben GAO, Jiang LI. Research advances in improving the prognosis of recipients of fatty liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(12): 2967-2971. doi: 10.3969/j.issn.1001-5256.2021.12.049
    [7]Yuxuan LI, Wenya LIU. Research advances in the value of sarcopenia in the prognosis of patients after liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(6): 1469-1472. doi: 10.3969/j.issn.1001-5256.2021.06.052
    [8]Wang Han, Zuo XiangRong, Cao Quan. Predictive factors and interventions for prolonged mechanical ventilation after liver transplantation[J]. Journal of Clinical Hepatology, 2020, 36(7): 1658-1662. doi: 10.3969/j.issn.1001-5256.2020.07.047
    [9]Luo Qiong, Wang ChunMing, Liao HangYu, Chen KunLing, Pan MingXin. Value of the NDRG family in the diagnosis and prognostic evaluation of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1284-1288. doi: 10.3969/j.issn.1001-5256.2020.06.019
    [10]Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
    [11]Zhong LanHai, Ma DanDan, Zhang ZhiYong, Zhang Yi, Cai Xun. Expression of FAM134B in liver cancer and its association with prognosis: An analysis based on data mining[J]. Journal of Clinical Hepatology, 2019, 35(11): 2508-2512. doi: 10.3969/j.issn.1001-5256.2019.11.023
    [12]Lu YeFeng, Xia Qiang, Qiu BiJun, Feng MingXuan, Wan Ping. An analysis of related issues in long-term survival in children after liver transplantation[J]. Journal of Clinical Hepatology, 2019, 35(11): 2396-2401. doi: 10.3969/j.issn.1001-5256.2019.11.004
    [13]Li TianTian, Sun Jing, Wang Quan, Ding JunQiang, Wang Jia, Xue Hui, Zhang Tao, Duan XueZhang. Clinical effect of stereotactic body radiotherapy in treatment of patients with small hepatocellular carcinoma and related prognostic factors[J]. Journal of Clinical Hepatology, 2018, 34(8): 1702-1706. doi: 10.3969/j.issn.1001-5256.2018.08.022
    [14]Zhang Jing, Zhou XinMin. Disease assessment and prognosis of liver failure[J]. Journal of Clinical Hepatology, 2016, 32(9): 1673-1677. doi: 10.3969/j.issn.1001-5256.2016.09.008
    [15]Fang ZiYan, Jin Shuai, Li Gong. Efficacy and prognostic factors of intensity-modulated radiotherapy for large primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(6): 886-890. doi: 10.3969/j.issn.1001-5256.2015.06.014
    [16]阿丽亚·热哈提, Shi XiuJiang, Feng Juan, Ma HaiLin, Chen Lan, 希尔娜依·阿不都黑力力, He FangPing. Influencing factors for survival after liver transplantation: a prognostic analysis of 34 cases [J]. Journal of Clinical Hepatology, 2015, 31(8): 1314-1316. doi: 10.3969/j.issn.1001-5256.2015.08.032
    [17]Hua XiangWei, Xia Qiang, Zhang JianJun, Li QiGen, Xu Ning, Chen XiaoSong, Zhang Ming, Xue Feng, Han LongZhi, Wang Xin, Xia Lei, Luo Yi, Shen CongHuan, Xing TianYu, Xi ZhiFeng. Prognos is of living donor liver transplantation performed during different periods in infants with biliary atresia: a single- center experience with 101 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 18-22. doi: 10.3969/j.issn.1001-5256.2014.01.006
    [18]Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
    [19]Wan Jun, Fan ShangDa. Clinical and basic research on liver transplantation for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2012, 28(4): 243-244.
  • Cited by

    Periodical cited type(3)

    1. 何冰,王艺婷,李雪文,许建成. 长春市不同年龄段健康成人血清心肌酶谱水平观察. 检验医学与临床. 2024(02): 151-155 .
    2. 孔焱,李晓慧,王辉,李岩,孙悦,苗强. 间接法建立新疆克拉玛依地区常规肝功能和血脂生化项目参考区间. 国际检验医学杂志. 2024(07): 858-861+866 .
    3. 张春娇,黄蓉,蔡婷婷,顾进. 基于间接法建立肾功能检验项目的生物参考区间. 湖南师范大学学报(医学版). 2024(01): 43-47 .

    Other cited types(1)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 3.2 %FULLTEXT: 3.2 %META: 92.5 %META: 92.5 %PDF: 4.3 %PDF: 4.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.7 %其他: 5.7 %其他: 0.4 %其他: 0.4 %China: 0.7 %China: 0.7 %India: 0.4 %India: 0.4 %Russian Federation: 0.4 %Russian Federation: 0.4 %上海: 5.0 %上海: 5.0 %保定: 0.4 %保定: 0.4 %北京: 7.8 %北京: 7.8 %南宁: 0.4 %南宁: 0.4 %吉林: 1.4 %吉林: 1.4 %吉隆坡: 0.7 %吉隆坡: 0.7 %呼和浩特: 0.4 %呼和浩特: 0.4 %大连: 1.1 %大连: 1.1 %张家口: 3.9 %张家口: 3.9 %昆明: 1.1 %昆明: 1.1 %杭州: 0.4 %杭州: 0.4 %濮阳: 0.4 %濮阳: 0.4 %芒廷维尤: 29.2 %芒廷维尤: 29.2 %苏州: 1.1 %苏州: 1.1 %莫斯科: 0.7 %莫斯科: 0.7 %西宁: 37.4 %西宁: 37.4 %长春: 1.1 %长春: 1.1 %长治: 0.4 %长治: 0.4 %其他其他ChinaIndiaRussian Federation上海保定北京南宁吉林吉隆坡呼和浩特大连张家口昆明杭州濮阳芒廷维尤苏州莫斯科西宁长春长治

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (260) PDF downloads(62) Cited by(4)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return